C-C Shu
Overview
Explore the profile of C-C Shu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pang A, Lin S, Yang J, Wang P, Pan S, Wei Y, et al.
Int J Tuberc Lung Dis
. 2024 Feb;
28(2):73-80.
PMID: 38303039
The importance of early intravenous (IV) antibiotic use for complex lung diseases (MABC-LD) treatment remains unknown. A retrospective multi-centre observational study was conducted in Taiwan. Patients who were diagnosed with...
2.
Shu C, Tsai M, Lee J, Su T, Wen C
QJM
. 2024 Jan;
117(6):436-444.
PMID: 38291945
Background: While all-cause mortality is reportedly increased in preserved ratio impaired spirometry (PRISm), no remedial efforts have been suggested. Aim: To study the ability of physical activity (PA) on reducing...
3.
Shu C, Wright F, Naganathan V, Blyth F, Le Couteur D, Handelsman D, et al.
Aust Dent J
. 2022 Apr;
67(3):262-270.
PMID: 35373341
Background: Past research on social support and dental visits in older people has been limited by cross-sectional design, limited social support dimensions and non-representative samples. Methods: Data came from men...
4.
Pan S, Shu C, Feng J, Chien J, Wang J, Chan Y, et al.
Clin Microbiol Infect
. 2020 May;
27(3):467.e9-467.e14.
PMID: 32360207
Objective: Disease progression is a strong indicator of treatment for Mycobacterium avium complex lung disease (MAC-LD). The impact of MAC subspecies on the risk of disease progression remains uncertain in...
5.
Wu M, Shu C, Lin H
Int J Tuberc Lung Dis
. 2020 Feb;
24(1):133-134.
PMID: 32005319
No abstract available.
6.
Cho P, Wu C, Johnston J, Wu M, Shu C, Lin H
Int J Tuberc Lung Dis
. 2019 May;
23(5):555-562.
PMID: 31097063
<sec id="st1"> <title>BACKGROUND</title> Little is known about tuberculosis (TB) risk in the earlier stages of chronic kidney disease (CKD). </sec> <sec id="st2"> <title>OBJECTIVE</title> To investigate the relationship between CKD at...
7.
Tran J, Wright F, Takara S, Shu C, Chu S, Naganathan V, et al.
Aust Dent J
. 2019 Apr;
64(3):246-255.
PMID: 30972755
Background: The Concord Health and Ageing in Men Project (CHAMP) is a cohort study of the health of a representative sample of older Australian men. The aim of this paper...
8.
Lee M, Yang C, Shu C, Lin C, Wen Y, Lee S, et al.
Clin Microbiol Infect
. 2015 Feb;
21(3):250.e1-7.
PMID: 25658545
Very few studies have focused on the outcome and management of patients with a single sputum isolate of nontuberculous mycobacterium (NTM) on initial examination. Patients with a single isolate of...
9.
Lien Y, Wang J, Lee M, Shu C, Chen H, Hsieh C, et al.
Br J Cancer
. 2013 Oct;
109(11):2933-40.
PMID: 24129236
Background: Obstructive uropathy and chronic urinary tract infection increase the risk of urinary tract cancer. Urinary tuberculosis (UTB) can cause chronic urinary tract inflammation, lead to obstructive uropathy, and potentially...
10.
Shu C, Lee C, Lee M, Wang J, Yu C, Lee L
Int J Tuberc Lung Dis
. 2013 Jun;
17(7):934-9.
PMID: 23743313
Background: Hepatotoxicity with first-line drugs, a major complication of anti-tuberculosis treatment, has not been studied by time-dependent analysis. Design: Adult patients diagnosed with pulmonary tuberculosis (PTB) from 2005 to 2009...